Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive crawled date : 2022 - 07 - 28 save search
The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: -0.26%
H: 1.35%
C: 0.87%
biib059 lupus positive phase 2
Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
AGNPF | $0.089 178.69% 75K
|
Health Technology
|
| O: 0.12%
H: 1.62%
C: 1.62%
positive study phase 2
Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy
Published: 2022-07-28 (Crawled : 13:00) - biospace.com/
AKTX | $1.25 3.31% 3.2% 7.5K
|
Health Technology
|
| O: 3.63%
H: 0.0%
C: -1.23%
pasylated trials research pre-clinical therapeutics potential positive
Ionis announces positive topline results from Phase 2b clinical study of fesomersen, a potential novel anti-thrombotic treatment
Published: 2022-07-28 (Crawled : 13:00) - biospace.com/
IONS | $42.455 1.47% 1.45% 730K
|
Health Technology
|
| O: 1.92%
H: 0.1%
C: -0.99%
treatment topline potential positive results study phase 2b
Better Therapeutics Completes Pivotal Trial of BT-001 for Type 2 Diabetes and Announces Positive Secondary Endpoint Results Following the Earlier Announcement of Positive Primary Endpoint Results
Published: 2022-07-28 (Crawled : 12:00) - biospace.com/
BTTX | $0.006 -65.02% 340K
|
|
| O: 63.4%
H: 2.4%
C: -20.4%
bt-001 announcement trial therapeutics diabetes positive
Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study
Published: 2022-07-28 (Crawled : 12:00) - prnewswire.com
CELZ | $4.8201 0.21% 8.8K
|
|
| O: 7.79%
H: 4.5%
C: 0.68%
ovastem technology positive study
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
Published: 2022-07-28 (Crawled : 11:00) - ir.cyclerion.com
CYCN | $3.05 -12.54% 720
|
Health Technology
|
| O: 0.0%
H: 22.08%
C: 22.08%
cy6463 topline schizophrenia therapeutics positive
Euro Manganese Announces Positive Feasibility Study Base Case Results for the Chvaletice Manganese Project; After-Tax NPV8% of US$1.34 Billion, IRR of 21.9%
Published: 2022-07-28 (Crawled : 01:00) - globenewswire.com
SF | $78.28 0.51% 0.0% 790K
|
Finance
|
| O: 0.27%
H: 0.34%
C: 0.02%
positive study
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.